Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.69 |
| ▸ | USP2 | O75604 | 4/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | POLB | P06746 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 8/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29327090 | 0.73 | USP2 (0.83) | KMT2AUSP2MEN1POLBMAPT | |
| SCHEMBL5798106 | 0.73 | TDP1 (0.60) | KMT2AUSP2MEN1POLBMAPT | |
| SCHEMBL7944975 | 0.70 | MEN1 (0.74) | KMT2AUSP2MEN1POLBMAPT | |
| SCHEMBL16562029 | 0.69 | HPGD (0.78) | KMT2AUSP2MEN1POLBMAPT | |
| SCHEMBL4910026 | 0.69 | NPC1 (1.00) | KMT2AMEN1MAPTSMN1; SMN2LMNA | |
| SCHEMBL6206186 | 0.68 | RAB9A (0.72) | KMT2AMEN1POLBMAPTSMN1; SMN2 | |
| SCHEMBL21858370 | 0.68 | NPC1 (1.00) | KMT2AUSP2MEN1POLBMAPT | |
| SCHEMBL11337093 | 0.68 | RAB9A (0.64) | KMT2AMEN1POLBMAPTSMN1; SMN2 | |
| SCHEMBL11140770 | 0.68 | ADORA1 (0.65) | KMT2AMEN1POLBMAPTSMN1; SMN2 | |
| SCHEMBL20952199 | 0.67 | KMT2A (0.65) | KMT2AUSP2MEN1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034075-A1 | Sphingosine kinase inhibitors | THE PENNSYLVANIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2004-02-19 | — | — | US | claimed |
| US-20080280866-A1 | Method of Treating or Sepsis | HAUSER CARL J | 2008-11-13 | — | — | US | disclosed |
| US-7220764-B2 | Such as 5-(2,4-dihydroxy-benzylidene)-3-(4-methoxy-phenyl)-2-thioxo-thiazolidin-4 -one; for treating/preventing hyperproliferative disease, autoimmune disease, inflammatory disease, or allergy | THE PENNSYLVANIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220764-B2 | Such as 5-(2,4-dihydroxy-benzylidene)-3-(4-methoxy-phenyl)-2-thioxo-thiazolidin-4 -one; for treating/preventing hyperproliferative disease, autoimmune disease, inflammatory disease, or allergy | THE PENNSYLVANIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220764-B2 | Such as 5-(2,4-dihydroxy-benzylidene)-3-(4-methoxy-phenyl)-2-thioxo-thiazolidin-4 -one; for treating/preventing hyperproliferative disease, autoimmune disease, inflammatory disease, or allergy | THE PENNSYLVANIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034075-A1 | Sphingosine kinase inhibitors | SPHK1, SPHK2, S1PR1 | KMT2A 2067/4885USP2 2491/4885MEN1 2072/4885 |
| US-20080280866-A1 | Method of Treating or Sepsis | SPHK1, SPHK2, S1PR2 | KMT2A 4205/4885USP2 3144/4885MEN1 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.